Anika Therapeutics (STU:AKP) ROCE %: -13.52% (As of Mar. 2026)

What is Anika Therapeutics ROCE %?

Anika Therapeutics STU:AKP -0.76% 66 ROCE % is -13.52% as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 66/100 and a GF Value™ of €17.79 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anika Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -13.52%.

Anika Therapeutics (STU:AKP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anika Therapeutics ROCE % Related Terms

Anika Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics ROCE % Chart

Anika Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-5.93

1.19

0.30

-2.49

-5.99

Anika Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-9.58	-9.40	-7.50	1.53	-13.52

66GF Score

Anika Therapeutics Inc STU:AKP

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Anika Therapeutics ROCE % Calculation

Anika Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-9.438	/	( ( (193.617 - 22.257)	+	(162.491 - 18.709) )	/ 2 )
	=	-9.438	/	( (171.36	+	143.782)	/ 2 )
	=	-9.438	/	157.571
	=	-5.99 %

Anika Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-18.988	/	( ( (162.491 - 18.709)	+	(155.17 - 18.136) )	/ 2 )
	=	-18.988	/	( ( 143.782	+	137.034 )	/ 2 )
	=	-18.988	/	140.408
	=	-13.52 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -13.52% mean?

Anika Therapeutics (STU:AKP) has a ROCE % of -13.52% as of Mar. 2026.

Is Anika Therapeutics' ROCE % too high?

Anika Therapeutics' current ROCE % is -13.52%. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Anika Therapeutics' ROCE % compare to LFCR and DERM?

Anika Therapeutics' ROCE % of -13.52% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current ROCE % is -13.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Anika Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.79, compared to a current price of €13.00 — trading 26.9% below its estimated fair value. The current ROCE % is -13.52%. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current ROCE % is -13.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.00 is trading 26.9% below its estimated GF Value™ of €17.79. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

ROCE %: -13.52%
GF Value™: €17.79 vs. price of €13.00 (26.9% below fair value)
GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies LFCR DERM ASRT SIGA CPIX AKBA TKNO ORGO INCR CTOR XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges ANIK:USA

Address 32 Wiggins Avenue, Bedford, MA, USA, 01730

Website https://www.anika.com

Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

66GF Score

Get the complete analysis for STU:AKP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00

Price

€17.79

GF Value

View STU:AKP Analysis

See ROCE % data for all stocks →